To investigate the clinical value of magnesium isoglycyrrhizinate (MIG) in prevention of liver damage caused by Brucellosis.

Total of 214 cases with Brucellosis were randomly divided into the observation group (110 cases) and control group (104 cases). The patients in control group were given conventional combined anti-Brinellcoli treatment with doxycycline and rifamycin. The patients in observation group were added 150 mg/d MIG once a day on the base treatment of the control group, and changed into oral glycyrrhizic acid diamine 150 mg after 2 weeks, all for totally 6 weeks.

The aminotransferase abnormality rate were 36.5% and 14.6% (χ² = 13.70, P = 0.000), 29.8% and 12.7% (χ² = 9.39, P = 0.002) after 2 weeks treatment and 6.7% and 1.8% (χ² = 3.20, P = 0.74) after 4-6 weeks treatment for the patients in control group and the observation group, respectively. For the degree of liver damage, ALT were (153.3±76.9) U/L and (78.1±34.3) U/L (t = 2.28, P = 0.016), AST were (127.5±62.1) U/L and (62.2±31.8) U/L (t = 2.16, P = 0.024) for the patients in control group and the observation group, all with significant difference. The rate of rifamycin withdrawal were 30.8% and 10.9% (χ² = 12.91, P = 0.000) for the control group and the observation group, respectively.

MIG had a reliable clinical value in the prevention of the damage caused by Brucellosi.